Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective

Table 5 The top 10 cocited references related to olaparib and pancreatic cancer

Rank	Ref.	Title	Citations	Journal
1	Golan et al[11], 2019	Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic cancer	103	The New England Journal of Medicine
2	Kaufman et al[35], 2015	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation	56	Journal of Clinical Oncology
3	Farmer et al[36], 2005	Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy	52	Nature
4	Robson et al[10], 2017	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation	46	The New England Journal of Medicine
5	Bryant et al[37], 2005	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	44	Nature
6	Murai et al[38], 2012	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors	40	Cancer Research
7	Waddell et al[39], 2015	Whole genomes redefine the mutational landscape of pancreatic cancer	39	Nature
8	Fong et al[40], 2009	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers	37	The New England Journal of Medicine
9	Moore et al[21], 2018	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer	37	The New England Journal of Medicine
10	Conroy et al[4], 2011	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer	36	The New England Journal of Medicine